Baolingbao BiologyLtd Bilan de santé

Santé financière contrôle des critères 6/6

Baolingbao BiologyLtd possède un total de capitaux propres de CN¥2.0B et une dette totale de CN¥363.5M, ce qui porte son ratio d'endettement à 17.9%. Son actif total et son passif total sont CN¥2.7B et de CN¥642.1M. L'EBIT de Baolingbao BiologyLtd est CN¥109.4M ce qui fait que son ratio de couverture des intérêts 13.6. Elle dispose de liquidités et de placements à court terme de CN¥276.7M.

Informations clés

17.9%

Ratio d'endettement

CN¥363.52m

Dette

Ratio de couverture des intérêts	13.6x
Argent liquide	CN¥276.72m
Fonds propres	CN¥2.03b
Total du passif	CN¥642.07m
Total des actifs	CN¥2.68b

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Baolingbao BiologyLtd (SZSE:002286) Strong Profits May Be Masking Some Underlying Issues

Nov 05

Baolingbao Biology Co.,Ltd.'s (SZSE:002286) Shares Climb 36% But Its Business Is Yet to Catch Up

Oct 08

We Like These Underlying Return On Capital Trends At Baolingbao BiologyLtd (SZSE:002286)

Sep 30

Baolingbao Biology Co.,Ltd.'s (SZSE:002286) Business Is Yet to Catch Up With Its Share Price

Jul 03

Returns On Capital At Baolingbao BiologyLtd (SZSE:002286) Have Stalled

Jun 07

Earnings Troubles May Signal Larger Issues for Baolingbao BiologyLtd (SZSE:002286) Shareholders

May 06

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 002286 ( CN¥855.8M ) dépassent ses passifs à court terme ( CN¥585.5M ).

Passif à long terme: Les actifs à court terme de 002286 ( CN¥855.8M ) dépassent ses passifs à long terme ( CN¥56.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 002286 ( 4.3% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 002286 a été réduit de 39.5% à 17.9% au cours des 5 dernières années.

Couverture de la dette: La dette de 002286 est bien couverte par le flux de trésorerie opérationnel ( 48.2% ).

Couverture des intérêts: Les paiements d'intérêts de 002286 sur sa dette sont bien couverts par l'EBIT ( 13.6 x couverture).

Baolingbao BiologyLtd Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Baolingbao BiologyLtd (SZSE:002286) Strong Profits May Be Masking Some Underlying Issues

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.031 in 3Q 2023)

Baolingbao Biology Co.,Ltd.'s (SZSE:002286) Shares Climb 36% But Its Business Is Yet to Catch Up

Baolingbao Biology Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

We Like These Underlying Return On Capital Trends At Baolingbao BiologyLtd (SZSE:002286)

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.041 in 2Q 2023)

Baolingbao Biology Co.,Ltd.'s (SZSE:002286) Business Is Yet to Catch Up With Its Share Price

Investor sentiment improves as stock rises 19%

Baolingbao Biology Co.,Ltd. to Report First Half, 2024 Results on Jul 31, 2024

Returns On Capital At Baolingbao BiologyLtd (SZSE:002286) Have Stalled

High number of new directors

Earnings Troubles May Signal Larger Issues for Baolingbao BiologyLtd (SZSE:002286) Shareholders

Baolingbao Biology Co.,Ltd. Approves Directorate Appointments

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.05 in 1Q 2023)

Investor sentiment deteriorates as stock falls 19%

Baolingbao Biology Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Baolingbao Biology Co.,Ltd. Announces Implementation of Final Cash Dividend for 2023, Payable on 08 March 2024

New minor risk - Earnings quality

Baolingbao Biology Co.,Ltd. Proposes Cash Dividend for 2023

Full year 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.36 in FY 2022)

Baolingbao Biology Co.,Ltd., Annual General Meeting, Feb 28, 2024

Investor sentiment deteriorates as stock falls 18%

Baolingbao Biology Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.057 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.13 in 2Q 2022)

Investor sentiment improves as stock rises 17%

Baolingbao Biology Co.,Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Baolingbao Biology Co.,Ltd. Announces Implementation of Final Cash Dividend for 2022, Payable on 20 June 2023

Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.057 (vs CN¥0.27 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2021)

Baolingbao Biology Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 27, 2022

Baolingbao Biology Co.,Ltd. Announces Final Cash Dividend for the Year 2021

Baolingbao Biology Co.,Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to CN¥17.55

High number of new and inexperienced directors

Price target decreased to CN¥17.55

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.03 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.079 in 2Q 2020)

Baolingbao Biology Co.,Ltd. Announces Cash Dividend of A Shares for the Year 2020, Payment Date on June 3, 2021

Baolingbao Biology Co.,Ltd. Approves Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.02 (vs CN¥0.04 in 1Q 2020)

Baolingbao Biology Co.,Ltd. Proposes Final Cash Dividend for the Year 2020

Baolingbao Biology Co.,Ltd. Approves the Board and Management Elections

New 90-day low: CN¥9.17

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥10.52

Market pulls back on stock over the past week

Third quarter earnings released

New 90-day low: CN¥13.71

First half earnings released

New 90-day high - CN¥19.77

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines